PMV PHARMACEUTICALS INC (PMVP)
US69353Y1038 - Common Stock
Overall PMVP gets a fundamental rating of 3 out of 10. We evaluated PMVP against 588 industry peers in the Biotechnology industry. While PMVP has a great health rating, there are worries on its profitability. PMVP does not seem to be growing, but still is valued expensively.
1. Profitability
1.1 Basic Checks
In the past year PMVP has reported negative net income.
PMVP had a negative operating cash flow in the past year.
In the past 5 years PMVP always reported negative net income.
In the past 5 years PMVP always reported negative operating cash flow.
1.2 Ratios
Looking at the Return On Assets, with a value of -27.35%, PMVP is in the better half of the industry, outperforming 75.17% of the companies in the same industry.
Looking at the Return On Equity, with a value of -30.56%, PMVP belongs to the top of the industry, outperforming 80.99% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -27.35% | ||
| ROE | -30.56% | ||
| ROIC | N/A |
ROA(3y)-23.97%
ROA(5y)-21.19%
ROE(3y)-26.37%
ROE(5y)-22.89%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Profit Margin and Operating Margin and Gross Margin are not available for PMVP so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
PMVP has more shares outstanding than it did 1 year ago.
The number of shares outstanding for PMVP has been increased compared to 5 years ago.
There is no outstanding debt for PMVP. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
Based on the Altman-Z score of 0.14, we must say that PMVP is in the distress zone and has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of 0.14, PMVP is in the better half of the industry, outperforming 62.84% of the companies in the same industry.
PMVP has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 0.14 |
ROIC/WACCN/A
WACCN/A
2.3 Liquidity
A Current Ratio of 14.78 indicates that PMVP has no problem at all paying its short term obligations.
The Current ratio of PMVP (14.78) is better than 89.90% of its industry peers.
PMVP has a Quick Ratio of 14.78. This indicates that PMVP is financially healthy and has no problem in meeting its short term obligations.
PMVP has a Quick ratio of 14.78. This is amongst the best in the industry. PMVP outperforms 89.90% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 14.78 | ||
| Quick Ratio | 14.78 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an nice 10.49% over the past year.
EPS 1Y (TTM)10.49%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q27.91%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Revenue growth Q2QN/A
3.2 Future
PMVP is expected to show a small growth in Earnings Per Share. In the coming years, the EPS will grow by 1.95% yearly.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y2.05%
EPS Next 2Y-3.79%
EPS Next 3Y1.95%
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for PMVP. In the last year negative earnings were reported.
Also next year PMVP is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-3.79%
EPS Next 3Y1.95%
5. Dividend
5.1 Amount
No dividends for PMVP!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
PMV PHARMACEUTICALS INC
NASDAQ:PMVP (4/26/2024, 7:10:39 PM)
After market: 1.75 0 (0%)1.75
+0.04 (+2.34%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap90.02M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -27.35% | ||
| ROE | -30.56% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 14.78 | ||
| Quick Ratio | 14.78 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)10.49%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y2.05%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y